These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30947657)

  • 81. Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer.
    Shang C; Guo Y; Zhang J; Huang B
    Cancer Chemother Pharmacol; 2016 May; 77(5):1061-7. PubMed ID: 27056384
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Induction/reversal of drug resistance in gastric cancer by non-coding RNAs (Review).
    Chen C; Tang X; Liu Y; Zhu J; Liu J
    Int J Oncol; 2019 May; 54(5):1511-1524. PubMed ID: 30896792
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Identification of lncRNA biomarkers in lung squamous cell carcinoma using comprehensive analysis of lncRNA mediated ceRNA network.
    Li R; Yang YE; Jin J; Zhang MY; Liu X; Liu XX; Yin YH; Qu YQ
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3246-3258. PubMed ID: 31364871
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Discovery of a novel six-long non-coding RNA signature predicting survival of colorectal cancer patients.
    Fan Q; Liu B
    J Cell Biochem; 2018 Apr; 119(4):3574-3585. PubMed ID: 29227531
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Prediction of candidate RNA signatures for recurrent ovarian cancer prognosis by the construction of an integrated competing endogenous RNA network.
    Wang X; Han L; Zhou L; Wang L; Zhang LM
    Oncol Rep; 2018 Nov; 40(5):2659-2673. PubMed ID: 30226545
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Dysregulation of long non-coding RNA in breast cancer: an overview of mechanism and clinical implication.
    Wang J; Ye C; Xiong H; Shen Y; Lu Y; Zhou J; Wang L
    Oncotarget; 2017 Jan; 8(3):5508-5522. PubMed ID: 27732939
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Identification of a serum circulating lncRNA panel for the diagnosis and recurrence prediction of bladder cancer.
    Duan W; Du L; Jiang X; Wang R; Yan S; Xie Y; Yan K; Wang Q; Wang L; Zhang X; Pan H; Yang Y; Wang C
    Oncotarget; 2016 Nov; 7(48):78850-78858. PubMed ID: 27793008
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Getting to know ovarian cancer: Focusing on the effect of LncRNAs in this cancer and the effective signaling pathways.
    Alzahrani AA; Almajidi YQ; Jasim SA; Hjazi A; Olegovich BD; Alkhafaji AT; Abdulridui HA; Ahmed BA; Alawadi A; Alsalamy A
    Pathol Res Pract; 2024 Feb; 254():155084. PubMed ID: 38244434
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Long non-coding RNAs towards precision medicine in gastric cancer: early diagnosis, treatment, and drug resistance.
    Yuan L; Xu ZY; Ruan SM; Mo S; Qin JJ; Cheng XD
    Mol Cancer; 2020 May; 19(1):96. PubMed ID: 32460771
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Reversal of Radiotherapy Resistance of Ovarian Cancer Cell Strain CAOV3/R by Targeting lncRNA CRNDE.
    Yang W; Li X; Zhao L; Zhao F
    J Healthc Eng; 2021; 2021():8556965. PubMed ID: 34540189
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Chemoresistance and targeted therapies in ovarian and endometrial cancers.
    Brasseur K; Gévry N; Asselin E
    Oncotarget; 2017 Jan; 8(3):4008-4042. PubMed ID: 28008141
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The Emerging Role of Non-coding RNAs in Drug Resistance of Ovarian Cancer.
    Lan H; Yuan J; Zeng D; Liu C; Guo X; Yong J; Zeng X; Xiao S
    Front Genet; 2021; 12():693259. PubMed ID: 34512721
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Role of Bioinformatics Analysis in Early Differential Diagnosis of Ovarian Cancer.
    Zhang L; Zhao Y; Li L; Xin H
    Contrast Media Mol Imaging; 2022; 2022():6129817. PubMed ID: 36185577
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Novel Approaches in Ovarian Cancer Research against Heterogeneity, Late Diagnosis, Drug Resistance, and Transcoelomic Metastases.
    Erol A; Niemira M; Krętowski AJ
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31146417
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A Review of IGF1 Signaling and IGF1-related Long Noncoding RNAs in Chemoresistance of Cancer.
    Liu L; Li X
    Curr Cancer Drug Targets; 2020; 20(5):325-334. PubMed ID: 32186268
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Nanocarrier-delivered small interfering RNA for chemoresistant ovarian cancer therapy.
    Zou M; Du Y; Liu R; Zheng Z; Xu J
    Wiley Interdiscip Rev RNA; 2021 Sep; 12(5):e1648. PubMed ID: 33682310
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Patient-derived organoids in ovarian cancer: Current research and its clinical relevance.
    Kumar S; Raina M; Tankay K; Ingle GM
    Biochem Pharmacol; 2023 Jul; 213():115589. PubMed ID: 37196684
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Tumor microenvironment manipulates chemoresistance in ovarian cancer (Review).
    Zhang Q; Ding J; Wang Y; He L; Xue F
    Oncol Rep; 2022 May; 47(5):. PubMed ID: 35362546
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Re: "Noncoding RNAs Interplay in Ovarian Cancer Therapy and Drug Resistance" by Liu et al.
    Özdemir BG
    Cancer Biother Radiopharm; 2024 Feb; 39(1):102. PubMed ID: 38109222
    [No Abstract]   [Full Text] [Related]  

  • 100. Long noncoding RNAs as therapeutic targets to overcome chemoresistance in ovarian cancer.
    Chen L; Wang J; Liu Q
    Front Cell Dev Biol; 2022; 10():999174. PubMed ID: 36105363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.